既往肾下腹主动脉修复与否对开窗分支型腔内主动脉修复早期与中期结局的比较
回顾性分析两个高容量主动脉中心2010-2019年连续222例开窗分支型腔内修复肾旁/胸腹主动脉瘤患者,其中58例(26.1%)有既往肾下修复(EVAR 33例、OAR 25例),164例(73.9%)为原发。两组技术成功率、30天主要不良事件、5年生存率及再干预率无显著差异,但既往修复组5年内漏I/III型免除率及瘤囊增大>5mm免除率显著更低。
要点
- 既往肾下修复患者F-BEVAR技术成功率94.8%,与原发组98.8%无显著差异(p=.08)。
- 既往修复组5年内漏I/III型免除率57.1%,显著低于原发组66.1%(p=.03)。
- 既往修复组5年瘤囊增大>5mm免除率48.6%,显著低于原发组77.5%(p=.002)。
核心结论
- F-BEVAR用于既往肾下修复患者与原发动脉瘤患者同样安全可行。
- 观察到靶血管相关内漏增加,可能导致随访期间瘤囊缩小免除率降低。
- 5年再干预率和靶血管通畅率相似,中期总体治疗效果仍满意。
研究设计与样本
- 回顾性分析两个高容量主动脉中心2010-2019年连续F-BEVAR病例。
- 共纳入222例连续患者,58例(26.1%)有既往肾下修复(EVAR 33例、OAR 25例),164例(73.9%)为原发肾旁/胸腹主动脉瘤。
- 主要终点为技术成功、30天死亡率和总生存率;次要终点包括30天主要不良事件、内漏I/III型免除率、再干预、瘤囊增大和靶血管一期通畅率。
主要发现
- 既往修复组年龄更大(平均75.1岁 vs 71.6岁,p=.005),女性比例更低(8.6% vs 29.3%,p=.002)。
- 全队列技术成功率97.8%(n=217),两组分别为94.8% vs 98.8%(p=.08)。
- 30天主要不良事件率既往修复组44.8% vs 原发组54.9%(p=.59)。
- 5年生存率原发组61.6% vs 既往修复组61.3%(p=.67)。
- 5年内漏I/III型免除率既往修复组57.1% vs 原发组66.1%(p=.03),主要归因于靶血管相关内漏(IC型和/或IIIC型)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to compare short- and mid-term outcomes of fenestrated-branched endovascular repair (F-BEVAR) of pararenal (PRAA)/thoracoabdominal (TAAA) aortic aneurysms in patients with or without prior endovascular/open (EVAR/OAR) infrarenal aortic repair. METHODS: Data from consecutive F-BEVAR (2010-2019) at two high-volume aortic centers were retrospectively reviewed. Primary endpoints were technical success, 30-day mortality, and overall survival. Secondary endpoints included 30-day major adverse events (MAE), freedom from type I/III endoleaks, reinterventions, sac expansion, and target vessel (TV) primary patency. RESULTS: A total of 222 consecutive patients were included for analysis; of these 58 (26.1%) had prior infrarenal repair (EVAR=33, OAR=25) and 164 (73.9%) had native PRAA/TAAA. At baseline, patients with prior infrarenal repair were older (mean age=75.1 vs 71.6 years, p=.005) and the proportion of females was lower (8.6% vs 29.3%, p=.002). Technical success was 97.8% (n=217) in the entire cohort, without any significant differences between study groups (94.8% vs 98.8%, p=.08). At 30 days, there were no significant differences between patients with prior infrarenal repair as compared with those without in rate of MAE (44.8% vs 54.9%, p=.59). The 5-year estimate of survival for those who underwent native aortic repair was 61.6%, versus 61.3% for those who had a previous repair (p=.67). The 5-year freedom from endoleaks I/III estimates were significantly lower in patients who had prior infrarenal repair as compared with patients undergoing treatment of native aneurysms (57.1% vs 66.1%, p=.03), mainly owing to TV-related endoleaks (ie, type IC and/or IIIC endoleaks). No significant differences were found between study groups in rates of reinterventions and TV primary patency. Five-year estimates of freedom from sac increase >5mm were significantly lower in patients who received F-BEVAR after previous infrarenal repair as compared with those who underwent treatment of native aneurysms (48.6% vs 77.5%, p=.002). CONCLUSIONS: F-BEVAR is equally safe and feasible for treatment of patients with prior infrarenal repair as compared with those undergoing treatment for native aneurysms. Increased rates of TV-related endoleaks were observed which could lead to lower freedom from aneurysm sac shrinkage during follow-up. Nevertheless, the 5-year rates of reinterventions and TV patency were similar, thereby indicating that overall effectiveness of treatment remained satisfactory at mid-term.
引用
- D'Oria M, Budtz-Lilly J, Lindstrom D, et al. Comparison of Early and Mid-Term Outcomes After Fenestrated-Branched Endovascular Aortic Repair in Patients With or Without Prior Infrarenal Repair. J Endovasc Ther. 2021. PMID: 34781751. doi:10.1177/15266028211058686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。